Strategic Investment


For Faster Service Call Toll-Free 1-877-524-8298 / Mon - Fri, 9 am - 7 pm EST

YES, James!

I want exclusive access to your forecasts and recommendations, so I know what’s coming… and can make more profitable investments in the months ahead. Please begin my risk-free trial subscription to Strategic Investment.

BEST DEAL! Save 61%

1 Year (12 monthly issues) for just $79! - 61% off the regular subscription price

I understand that in addition to 12 issues of the newsletter, I'll have free access to your weekly podcast, access to your members-only website, and receive a FREE copy of these Special Reports:

Free Report #1: The Millionaire Maker: How to Grab Windfall Profits in the $57 Billion Medical Cannabis Market ($29 value)

Free Report #2: Killing Cancer: How a Biotech Breakthrough Could Bring 1000% Profits ($29 value)


Free Report #3: The Global Mega Shocker: James Dale Davidson’s Direst Warning and How To Cash In On It Now ($29 value)

Free Report #4: The Amazon of Blockchain ($19 value)

Free Report #5: Serial Killers: 3 Companies on the Verge of Curing Cancer That Could Be Commercialized in the Next 48 Months ($29 value)

Free Report #6: Asymmetrical Investing: Contrarianism On Steroids  ($29 value)

Free Special Bonus:  One 1921 Morgan Silver Dollar - valuable and collectible item ($49 value)

GREAT DEAL! SAVE 50%

6 months (6 monthly issues) for just $39 - 50% off the regular subscription price

I understand that in addition to 6 issues of the newsletter, I'll have free access to your weekly podcast, and receive a FREE copy of these Special Reports:

Free Report #1: The Millionaire Maker: How to Grab Windfall Profits in the $57 Billion Medical Cannabis Market ($29 value)

Free Report #2: Killing Cancer: How a Biotech Breakthrough Could Bring Triple Digit Profits ($29 value)


10-Day Quick-Response Bonus:

I'm subscribing within 10 days. Please send me a FREE copy of your new special report:

IMPORTANT NOTICE AND DISCLAIMER: All investments are subject to risk, which must be considered on an individual basis before making any investment decision. Strategic Investment is the publisher of these materials and is not responsible for errors and omissions. This publication is intended solely for information and educational purposes and is not to be construed, under any circumstances, as an offer to buy or sell, or a solicitation to buy or sell or trade, or as a personal recommendation to buy or sell or trade in any securities or commodities named in these materials. These materials are a paid advertisement. Information gathered to create these materials is from sources believed to be reliable, but is in no way guaranteed. Furthermore, you cannot be assured that you will profit or that any losses can or will be limited. It is important to know that no guarantee of any kind is implied or possible where projections of future conditions in the markets are attempted. Hypothetical or simulated performance results have certain inherent limitations as to liquidity and execution, among other variables. All readers should consult their own personal investment adviser before making an investment decision. Investing in securities is highly speculative and carries a great deal of risk, especially as to newer companies with comparatively short operating histories and limited earnings. This report contains projections regarding future operating results, which are forward-looking statements. Those projections were derived from sources that have not been verified independently. All forward-looking statements are believed to have a reasonable basis, but are subject to risks, uncertainties and other factors that could cause actual results to differ materially from future results expressed, projected or implied by such forward-looking statements. Those projections should not be considered a comprehensive representation of the featured company’s future performance. Strategic Investment is a paid circulation newsletter and is not a financial analyst, investment advisor or broker/dealer. These materials are a solicitation for subscriptions for the newsletter and a paid promotional advertisement of Isracann Biosciences Inc. (OTC: ISCNF). Strategic Investment expects to generate new subscriber revenue as a result of this advertisement. This paid advertisement includes a stock profile of Isracann Biosciences Inc. (ISCNF). Strategic Investment is an investment newsletter being advertised herein. This paid advertisement is intended solely for information and educational purposes and is not to be construed under any circumstances as an offer to buy or sell, or as a solicitation to buy or sell, any securities. Strategic Investment assumes no obligation to provide any future views in support of the highlighted company. In an effort to enhance public awareness of ISCNF and its securities, Isracann Biosciences Inc. (Payor) provided advertising agencies with a total budget of approximately two million fifty-seven thousand one hundred seventy-four dollars to cover the costs associated with creating, printing and distribution of this advertisement and other elements of this campaign in an effort to build investor awareness. Payor has represented to advertising agencies in writing that Payor has conducted a reasonable investigation or obtained appropriate written representations from ISCNF that it is the source of all funds that have been or will be paid to advertising agencies for this advertising campaign. Strategic Investment was paid thirty thousand dollars as a research fee. In addition, Strategic Investment may generate new subscription revenue, the amount of which is unknown at this time, as a result of the distribution of these materials. The advertising agencies involved in this campaign relied on information provided by Isracann Biosciences Inc. The advertising agencies will retain as their compensation any excess sums after all expenses are paid. As of the date these materials are first disseminated, neither Strategic Investment, the advertising agencies, nor any of their respective officers, principals or affiliates (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) own or beneficially own any securities of Isracann Biosciences Inc., and will not purchase, receive or otherwise acquire any securities of Isracann Biosciences Inc. for a period of 90 days following the date this advertising campaign is concluded. The Payor has represented in writing to Strategic Investment and the advertising agencies that (1) its officers, directors, and principals (as defined in the Securities Act of 1933, as amended, and Rule 501(b) promulgated thereunder) are beneficial owners of the Company; (2) the Issuer and its officers, directors, and principals will not sell or otherwise disposed of any securities for a period of ninety (90) days following the conclusion of the Campaign; (3) neither Issuer and its officers, directors, and principals will purchase, receive or otherwise acquire any additional securities of the Company for a period of ninety (90) days following the conclusion of the Campaign; (4) Payor has implemented appropriate procedures to ensure the implementation of the foregoing representations and warranties to Strategic Investment and the advertising agencies. If successful, this advertisement will increase investor and market awareness, which may result in an increased number of shareholders owning and trading the securities of ISCNF, increased trading volume, and possibly an increased share price of ISCNF’s securities, which may be temporary. This advertisement, the advertising agencies and Strategic Investment do not purport to provide a complete analysis of ISCNF’s financial position, operations or prospects, and this is not to be construed as a recommendation by Strategic Investment. as an offer to buy or sell any security or as investment advice. An offer to buy or sell can only be made with accompanying disclosure documents and only in states and provinces for which they are approved. They are not, and do not purport to be, broker-dealers or registered investment advisors. This advertisement is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent publicly- available information about ISCNF and its industry. Further, readers are specifically urged to read and carefully consider the Risk Factors identified and discussed in ISCNF’s SEC filings. Investing in securities, particularly microcap securities such as ISCNF, is inherently speculative and carries a high degree of risk. Past performance does not guarantee future results. This advertisement is based exclusively on information generally available to the public and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the advertising agencies and Strategic Investment cannot guarantee the accuracy or completeness of the information The advertising agencies and Strategic Investment note that statements contained herein that look forward in time, which include everything other than historical information, involve risks and uncertainties that may affect ISCNF’s actual results of operations. Factors that could cause actual results to differ include the size and growth of the market for ISCNF’s products and/or services, the company’s ability to fund its capital requirements in the near term and long term, pricing pressures, etc. Strategic Investment is the publisher’s trademark. All trademarks used in this advertisement other than Strategic Investment are the property of their respective trademark holders and no endorsement by such owners of the contents of this advertisement is made or implied. The advertising agencies and Strategic Investment are not affiliated, connected, or associated with, and are not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made to any rights in any third-party trademarks. More information can be found on the Isracann Biosciences Inc. website (https://Isracann.com/). As with any low-priced stock, investors should use only risk capital they are willing to lose or hold for long-term investing.